| Combination of | |
|---|---|
| Lamivudine | nucleoside reverse transcriptase inhibitor |
| Nevirapine | non-nucleoside reverse transcriptase inhibitor |
| Stavudine | nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Triomune, others |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Lamivudine/nevirapine/stavudine (3TC/NVP/d4T) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.[1] It contains lamivudine, nevirapine, and stavudine.[1] It is either used by itself or along with other antiretrovirals.[1] It is taken by mouth twice a day.[1]
It is on the World Health Organization's List of Essential Medicines.[2] As of 2015, it is not commercially available in the United States.[3]
YouTube Encyclopedic
-
1/5Views:136 7604 3651 28549 8814 149
-
Antiretroviral Drugs Pharmacology / Mechanism of Action
-
HIV ZLN PATIENT ,DRUG ZLN DETAIL description
-
ANTIRETROVIRAL | AIDS | HIV
-
Efek Samping Obat HIV (ARV) Zidovudine(AZT), Lamuvudine(3TC) dan Stavudine(d4T), Dr. Teguh Haryono
-
Pharmacology 879 b AntiViral Drugs Retroviral AIDS HIV Treatment Retrovirus NRTI Zidovudine HAART
Transcription
Medical uses
It is a common first line treatment in the developing world.[4]
Adverse effects and safety
The medication is generally well tolerated.[5] Side effects are those of the underlying medications.[1] This may include rash, numbness, pancreatitis, and high blood lactate levels.[5] Use is not recommended in those with significant liver problems.[5] It is unclear if use in pregnancy is safe for the baby and recommendations include starting in the second trimester if possible.[5]
References
- ^ a b c d e World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 160. hdl:10665/44053. ISBN 9789241547659.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ Kasper DL, Fauci AS, Hauser S, Longo D, Jameson JL, Loscalzo J (2015). Harrison's Principles of Internal Medicine 19/E (Vol.1 & Vol.2). McGraw Hill Professional. p. 1277. ISBN 9780071802161. Archived from the original on 2016-12-20.
- ^ Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW (April 2006). "Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults". The Cochrane Database of Systematic Reviews. 2006 (2): CD004535. doi:10.1002/14651858.CD004535.pub2. PMC 8407055. PMID 16625606.
- ^ a b c d "Nevirapine/stavudine/lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
External links
- "Lamivudine mixture with Nevirapine and Stavudine". Drug Information Portal. U.S. National Library of Medicine.
This page was last edited on 6 October 2023, at 04:05